share_log

Shareholders in Hualan Biological Engineering (SZSE:002007) Are in the Red If They Invested Three Years Ago

Shareholders in Hualan Biological Engineering (SZSE:002007) Are in the Red If They Invested Three Years Ago

如果股东在三年前投资华兰生物工程(深圳证券交易所:002007),那么他们现在的投资亏损了。
Simply Wall St ·  06/07 18:29

Investing in stocks inevitably means buying into some companies that perform poorly. Long term Hualan Biological Engineering Inc. (SZSE:002007) shareholders know that all too well, since the share price is down considerably over three years. So they might be feeling emotional about the 52% share price collapse, in that time. More recently, the share price has dropped a further 8.9% in a month. However, we note the price may have been impacted by the broader market, which is down 5.8% in the same time period.

投资股票不可避免地意味着买入一些表现不佳的公司。长期持有华兰生物工程股份有限公司股票的股东深有体会,因为股价在过去三年中大幅下跌。因此,他们可能会对股价暴跌52%感到情绪化。最近一个月,股价进一步下跌了8.9%。但是,我们注意到价格可能受到了更广泛市场的影响,在同一时期内下跌了5.8%。

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

由于股东们长期以来都亏损了,因此让我们回顾过去一段时间的基本面,看看是否一直与收益相一致。

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

虽然市场是一个强大的定价机制,但股价反映的不仅仅是企业的基本业绩,还有投资者的情绪。一个不完美但简单的方式来考虑公司市场意识的变化是比较每股收益(EPS)的变化和股价的变化。

Hualan Biological Engineering saw its EPS decline at a compound rate of 5.1% per year, over the last three years. The share price decline of 22% is actually steeper than the EPS slippage. So it's likely that the EPS decline has disappointed the market, leaving investors hesitant to buy.

华兰生物工程的每股收益在过去三年中以年复合率5.1%的速度下降。股价下跌了22%,实际上比每股收益的下跌要陡峭。因此,每股收益的下降可能令市场失望,使投资者不愿购买。

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

该公司的每股收益(随时间的推移)如下图所示(单击可查看确切数字)。

earnings-per-share-growth
SZSE:002007 Earnings Per Share Growth June 7th 2024
SZSE:002007 每股收益增长于2024年6月7日

It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

值得注意的是,该公司的首席执行官的薪酬低于同样规模的公司的中位数。但是,虽然首席执行官的报酬始终值得检查,但真正重要的问题是公司是否能够继续增长收益。在购买或出售股票之前,我们始终建议对历史增长趋势进行仔细研究,此处提供了相关资讯。

A Different Perspective

不同的观点

While the broader market lost about 12% in the twelve months, Hualan Biological Engineering shareholders did even worse, losing 17% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 2% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Hualan Biological Engineering .

尽管更广泛的市场在过去十二个月中损失了约12%,但华兰生物工程的股东表现得更差,损失了17%(即使包括股息在内)。尽管如此,在下行市场中,某些股票过度抛售是不可避免的。关键是密切关注基本面的发展。不幸的是,去年的表现可能表明存在未解决的挑战,因为它比过去五年中的年化亏损2%还要糟糕。一般来说,长期的股价疲 weakness 可能是个坏迹象,不过一些与众不同的投资者可能希望研究该股,以期逆转形势。虽然非常值得考虑市场条件可能对股价造成的不同影响,但有其他更加重要的因素。因此,您应该注意到我们在华兰生物工程中发现的1种警示信号。

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

对于那些喜欢寻找获胜投资的人来说,最近有内部购买的低估公司免费列表可能是一个很好的选择。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发